Craniosynostosis Cell Models for Research

Craniosynostosis is a congenital anomaly characterized by premature fusion of one or more cranial sutures, affecting approximately 1 in 2,000 to 2,500 live births worldwide (WHO, 2023). The condition leads to skull deformity, increased intracranial pressure, and potential neurodevelopmental impairment. Syndromic forms, such as Apert, Crouzon, and Pfeiffer syndromes, account for about 15% of cases and are primarily linked to mutations in FGFR2, FGFR3, TWIST1, and MSX2. Non-syndromic craniosynostosis is more common and often involves complex genetic and environmental interactions. Risk factors include advanced paternal age, maternal smoking, and certain medications. Surgical intervention is the primary treatment, but recurrence and long-term cognitive outcomes remain challenges. Five-year survival for isolated craniosynostosis is generally excellent (>95%), but syndromic cases with multisystem involvement have higher morbidity and mortality (NCI, 2024).

Craniosynostosis serves as a paradigm for studying bone development, suture biology, and signaling pathways. Its genetic heterogeneity, with well-defined mutations in FGFR, TWIST, and BMP pathways, makes it ideal for mechanistic studies. Public datasets such as ClinVar, COSMIC, and NCBI Gene provide extensive mutation data. Open questions include the role of epigenetic regulation, the interplay between mechanical forces and genetic predisposition, and the identification of molecular targets for non-surgical therapies. Research models, including gene-edited cell lines, are essential to dissect these mechanisms and accelerate drug discovery.

Although craniosynostosis is not a malignancy, the dysregulated signaling pathways overlap with those in cancer. Key pathways include:

1. FGF signaling: Activating mutations in FGFR2 (e.g., S252W, P253R) lead to prolonged downstream signaling through MAPK and PI3K/AKT, promoting osteoblast proliferation and premature suture fusion.

2. TWIST1-BMP axis: TWIST1 haploinsufficiency results in increased BMP signaling, enhancing osteogenic differentiation.

3. Wnt/β-catenin pathway: Aberrant activation in suture mesenchyme contributes to osteoblast differentiation and suture closure.

4. TGF-β signaling: Modulates osteoblast and osteoclast activity; dysregulation can tip the balance toward bone formation.

Data from ClinVar, COSMIC, and NCBI Gene (2024).

• • FGF-MAPK cascade:
• • FGFR2 mutations cause constitutive activation.
• • Downstream effectors: RAS, RAF, MEK, ERK.
• • Leads to increased proliferation and osteogenic gene expression.
• • PI3K/AKT/mTOR pathway:
• • Activated by FGFR signaling.
• • Promotes cell survival and growth.
• • BMP-SMAD pathway:
• • TWIST1 normally inhibits RUNX2; loss of TWIST1 enhances BMP signaling.
• • SMAD1/5/8 phosphorylation drives osteoblast differentiation.
• • Wnt/β-catenin:
• • Stabilization of β-catenin in suture mesenchyme.
• • Upregulates RUNX2 and ALP.
• • TGF-β:
• • Context-dependent effects on osteoblast proliferation and differentiation.

Organoids derived from suture mesenchyme or induced pluripotent stem cells (iPSCs) offer advantages: they recapitulate tissue architecture, allow co-culture of osteogenic and fibroblast lineages, and enable high-throughput drug screening. Patient-derived iPSC organoids carrying FGFR2 or TWIST1 mutations are valuable for personalized medicine.

• • Genetically engineered mouse models (GEMMs):
• • Fgfr2 S252W knock-in mice exhibit craniosynostosis and serve as a model for Apert syndrome.
• • Twist1 heterozygous mice show coronal suture fusion.
• • Msx2 transgenic mice develop craniosynostosis.
• • Patient-derived xenografts (PDX):
• • Limited due to the non-malignant nature, but can be used to study suture fusion in immunodeficient mice.
• • Induced models:
• • Zebrafish with fgfr2 mutations.
• • Chick embryos with retroviral overexpression of mutant FGFR2.
• • Advantages: GEMMs allow study of developmental timing and tissue-specific effects; zebrafish enable rapid genetic manipulation and live imaging.

CRISPR/Cas9 technology enables the creation of isogenic cell lines that differ only by a specific mutation, eliminating confounding genetic background. Examples include:

• • FGFR2 S252W knock-in in human osteoblast cell lines to model Apert syndrome.
• • TWIST1 knockout in suture mesenchymal cells to study haploinsufficiency.
• • RUNX2 knock-in to mimic gain-of-function.
• • MSX2 P148H knock-in to investigate enhanced osteogenesis.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are engineered using CRISPR knock-out, knock-in, or reporter lines and are quality-controlled for genomic integrity and functional activity. They enable precise target validation and drug screening without the need for patient samples.

Gene-edited cell lines allow systematic interrogation of gene function. For example:

• • Knockout of TWIST1 in osteoblast precursors confirms its role as a negative regulator of osteogenesis.
• • Knock-in of FGFR2 S252W demonstrates ligand-independent activation and downstream MAPK signaling.
• • CRISPR interference (CRISPRi) screens can identify modifiers of suture fusion.

These models validate candidate genes from GWAS and exome sequencing, linking genotype to phenotype.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput drug screens. For instance, comparing FGFR2 S252W knock-in cells to isogenic wild-type controls allows identification of selective FGFR inhibitors. Resistance modeling can be performed by long-term exposure to inhibitors and subsequent whole-exome sequencing to uncover secondary mutations. Such studies inform combination therapies and predict clinical outcomes.

CRISPR synthetic lethality screens in craniosynostosis models can identify genetic dependencies. For example, cells with TWIST1 haploinsufficiency may be sensitive to inhibition of BMP signaling, revealing potential biomarkers. Similarly, FGFR2-mutant cells may depend on PI3K/AKT signaling, suggesting pathway components as biomarkers. These findings can guide patient stratification and targeted therapy.